株式

株式会社Liquid Mine

Tokyo, JP · 1 known investors

liquidmine.co.jp ↗

Liquid Mine develops MyRD®, a liquid biopsy-based genomic testing system that creates personalized diagnostic tests for leukemia and other cancers by analyzing individual patient genetic mutations. The company aims to advance precision medicine in oncology by making genomic testing more accessible, particularly in Japan, through collaboration with Tokyo University's Institute of Medical Science.

Investors · 1

AS

aSTARTTokyo